Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
QIAGEN receives U.S. FDA Emergency Use Authorization for fast and easy-to-use digital test to detect SARS-CoV-2 coronavirus antibodies
QGEN earnings call for the period ending March 31, 2021.
QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.
View more earnings on CVSSee more from BenzingaClick here for options trades from BenzingaPremier Beats On Q3 Earnings, Raises 2021 OutlookQiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NEW YORK, NY / ACCESSWIRE / May 4, 2021 / QIAGEN NV (NYSE:QGEN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 9:00 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S.-German genetic testing company Qiagen NV reported slightly better-than-expected quarterly earnings on Monday as sales growth in its non-coronavirus products added to high demand for COVID-19 tests. Qiagen's products include several types of COVID-19 tests that helped it to boost sales over the past year and recover from a difficult 2019 that included profit warnings, a slump in China business and a CEO departure. "We have made multiple product expansions to our non-COVID related portfolio...